Armistice Capital LLC grew its stake in FibroGen, Inc. (NASDAQ:FGEN - Free Report) by 23.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 9,764,000 shares of the biopharmaceutical company's stock after purchasing an additional 1,872,000 shares during the period. Armistice Capital LLC owned approximately 9.93% of FibroGen worth $8,654,000 at the end of the most recent reporting period.
- Why did Sarepta Therapeutics Stock Plummet?
A number of other institutional investors have also modified their holdings of the stock. SG Americas Securities LLC increased its holdings in shares of FibroGen by 79.8% in the fourth quarter. SG Americas Securities LLC now owns 112,783 shares of the biopharmaceutical company's stock valued at $100,000 after purchasing an additional 50,073 shares during the period. Public Employees Retirement System of Ohio grew its holdings in FibroGen by 1,472.7% during the third quarter. Public Employees Retirement System of Ohio now owns 176,593 shares of the biopharmaceutical company's stock worth $152,000 after acquiring an additional 165,364 shares during the period. Primecap Management Co. CA grew its holdings in FibroGen by 7.7% during the third quarter. Primecap Management Co. CA now owns 14,724,968 shares of the biopharmaceutical company's stock worth $12,706,000 after acquiring an additional 1,047,380 shares during the period. Connor Clark & Lunn Investment Management Ltd. acquired a new position in FibroGen during the third quarter worth $94,000. Finally, Algert Global LLC grew its holdings in FibroGen by 488.4% during the third quarter. Algert Global LLC now owns 161,550 shares of the biopharmaceutical company's stock worth $139,000 after acquiring an additional 134,094 shares during the period. Institutional investors and hedge funds own 72.71% of the company's stock.
FibroGen Trading Up 2.5 %
FGEN opened at $1.21 on Thursday. The business's fifty day moving average is $1.32 and its two-hundred day moving average is $1.34. FibroGen, Inc. has a one year low of $0.33 and a one year high of $19.32.
FibroGen (NASDAQ:FGEN - Get Free Report) last posted its earnings results on Monday, May 6th. The biopharmaceutical company reported ($0.33) EPS for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.02). The business had revenue of $55.90 million during the quarter, compared to the consensus estimate of $41.00 million. Analysts forecast that FibroGen, Inc. will post -1.05 earnings per share for the current fiscal year.
Analysts Set New Price Targets
Separately, William Blair reaffirmed a "market perform" rating on shares of FibroGen in a report on Monday. One investment analyst has rated the stock with a sell rating and four have given a hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus price target of $2.00.
Read Our Latest Stock Report on FibroGen
FibroGen Profile
(Free Report)
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.
Featured Stories
- Five stocks we like better than FibroGen
- Bank Stocks - Best Bank Stocks to Invest In
- Lululemon Stock Rallying Back to Its True Value
- 3 REITs to Buy and Hold for the Long Term
- Semtech Stock’s Breakout Could Have Another Leg Higher
- The How And Why of Investing in Oil Stocks
- REV Group, Inc. Stock Doubles in 12 Months, Will It Double Again?
Want to see what other hedge funds are holding FGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for FibroGen, Inc. (NASDAQ:FGEN - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
→ CEO of Biggest AI Chipmaker Just Dropped a Bombshell… (From Banyan Hill Publishing) (Ad)
Should you invest $1,000 in FibroGen right now?
Before you consider FibroGen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and FibroGen wasn't on the list.
While FibroGen currently has a "Reduce" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Ten Starter Stocks For Beginners to Buy Now
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
